Clinical response to immune checkpoint inhibition in patients with advanced skin cancers receiving concurrent ruxolitinib therapy for haematological malignancy

Br J Dermatol. 2021 Mar;184(3):564-566. doi: 10.1111/bjd.19604. Epub 2020 Nov 12.

N Haddad¹, J Delyon^{1

2

3}, S Trabelsi Messai⁴, F Herms¹, M T Leccia⁴, C Lebbe^{1

2

3}, J Whitney⁵, S Bhatia^{5

6}, N Basset-Seguin^{1

2

3}

¹ Department of Dermatology, AP-HP Saint-Louis Hospital, Paris, France.
² Department of Dermatology, Université de Paris VII Diderot, Sorbonne Université Cité, Paris, France.
³ INSERM HIPI, Université de Paris VII Diderot, Sorbonne Université Cité, Paris, France.
⁴ Dermatology Department, CHU de Grenoble, Grenoble, France.
⁵ Department of Medicine/Medical Oncology, University of Washington, Seattle, WA, USA.
⁶ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

No abstract available

Publication types